Analysis links DPP-4 inhibitors to reduced CVD risk in diabetes

09/25/2011 | (free registration)

A meta-analysis presented at the European Association for the Study of Diabetes showed that type 2 diabetes patients who took dipeptidyl peptidase–4 inhibitors had a 31% decreased risk of major cardiovascular events, compared with those taking a placebo or other treatments. However, the review has limitations, including that cardiovascular events were not the end point in any of the studies, and further investigation is needed, the lead researcher said.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA